Stocktoria
DEXCOM INC DXCM
DEXCOM INC (DXCM) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $4.7B at a 17.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-04 | Argus Research | Buy (main) |
| 2026-08-03 | Canaccord Genuity | Buy (main) |
| 2026-07-31 | Citigroup | Buy (main) |
| 2026-07-31 | RBC Capital | Outperform (main) |
| 2026-07-31 | Mizuho | Outperform (main) |
| 2026-07-31 | JP Morgan | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.298 |
| Retained earnings / assets | 0.384 |
| EBIT / assets | 0.144 |
| Equity / liabilities | 0.764 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DXCM | DEXCOM INC | 7/9 | 4.98 | 32.4 | +15.6% |
| RMD | RESMED INC | 8/9 | 8.65 | 20.7 | +9.8% |
| MMED | MiniMed Group, Inc. | 3/9 | 4.28 | — | +14.3% |
| WST | WEST PHARMACEUTICAL SERVICES INC | 7/9 | 9.34 | 47.2 | +6.3% |
| GMED | GLOBUS MEDICAL INC | 7/9 | 10.06 | 21.8 | +16.7% |
| PODD | INSULET CORP | 6/9 | 4.78 | 44.4 | +30.7% |
| ICUI | ICU MEDICAL INC/DE | 6/9 | 2.9 | — | -6.3% |
About DEXCOM INC
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
FAQ
Is DXCM financially healthy?
DEXCOM INC's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does DXCM pay a dividend?
No, DEXCOM INC does not currently pay a dividend.
How profitable is DXCM?
In FY2025, DEXCOM INC had a net margin of 17.9% and a return on equity of 30.5%.
Is DXCM overvalued or undervalued?
DEXCOM INC trades at about 43.4× trailing earnings — below its 10-year norm (10-year range 34.9×–218.9×, median 93.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for DXCM?
The average Wall-Street price target for DEXCOM INC is $93.44, about 2.9% above the recent price, from 25 analysts (consensus: strong buy).
Is DXCM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DEXCOM INC: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 32.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.